Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
News|Articles|March 2, 2026
Oncology Frontiers: Recapping a Milestone February for FDA Approvals
Author(s)Targeted Oncology Staff
Fact checked by: Sabrina Serani
FDA oncology updates in February 2026 deliver new approvals, oral and monthly dosing options, and key NDA reviews, easing treatment burden across hard-to-treat cancers.
Advertisement
Advertisement
February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some of the most challenging diagnoses in modern medicine. From the introduction of noninvasive technologies for pancreatic cancer to the streamlining of lung cancer treatments through subcutaneous delivery, these decisions emphasize a clear regulatory trend: prioritizing both clinical efficacy and patient quality of life.
Related to this article
Durvalumab plus enfortumab vedotin improved EFS and OS in MIBC and will be considered for FDA approval in the fourth quarter of 2026.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
US cancer deaths keep falling as lung cancer declines; smoking drops, screening rises, but rural and low-education gaps persist.
FDA approves belzutifan plus lenvatinib for advanced clear cell RCC after PD-1/PD-L1 therapy, based on PFS and response rate benefit vs cabozantinib.
Advisory panel backs Galleri blood test for adults 50+, citing strong specificity, mixed sensitivity, and follow-up impacts as FDA weighs approval.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
Advertisement
Advertisement